Sort
23,748 grants matching “melanoma”
Determining the clinical impact of gene expression testing in localized prostate cancer
$617,917Todd M. Morgan · University Of Michigan At Ann Arbor · R01 · FY2019 · CA
Investigating the PD-L1:NLRP3 signaling axis as a tumor intrinsic mechanism of adaptive resistance to anti-PD-1 antibody immunotherapy
$617,715Brent Allen Hanks · Univ Of North Carolina Chapel Hill · R37 · FY2025 · CA
Targeting BPTF in the Therapy of BRAF-mutant Melanoma
$617,648Mohammed Kashani-Sabet · California Pacific Med Ctr Res Institute · R01 · FY2021 · CA
Targeting BPTF in the Therapy of BRAF-mutant Melanoma
$617,648Mohammed Kashani-Sabet · California Pacific Med Ctr Res Institute · R01 · FY2020 · CA
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology.
$617,631Nicole Franziska Steinmetz · University Of California, San Diego · U01 · FY2020 · CA
Targeting BPTF in the Therapy of BRAF-mutant Melanoma
$617,524Mohammed Kashani-Sabet · California Pacific Med Ctr Res Institute · R01 · FY2018 · CA
Cellular Interactions with the Extracellular Matrix of the Tumor Microenvironment
$617,417Richard O Hynes · Massachusetts Institute Of Technology · U54 · FY2009 · CA
Rapamycin and IL-21 Conditioned CD8+ T Cells for Adoptive Cellular Therapy of Ov
$617,258Protul Shrikant · Roswell Park Cancer Institute Corp · P50 · FY2015 · CA
Mechanisms of Cross-talk Between EphrinB and Alternate Signaling Pathways
$617,257Ira Daar · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
DEFINING THE ROLE OF STEM CELL ACTIVATION IN INITIATING MELANOMA AND MELANOCYTIC TUMOR RECURRENCE
$617,020Cornell University · · FY2016 · Department of Defense
Tumor gene expression in vitro and in vivo
$617,011Douglas R. Lowy · Division Of Basic Sciences - Nci · ZIA · FY2011 · CA
ICON TARGETING OF TUMOR VASCULATURE AND TUMOR CELLS
$616,916Albert B Deisseroth · Sidney Kimmel Cancer Center · P01 · FY2007 · CA
Synthetic Compartments to Rewire Inflammatory Signaling and Augment Immune Cell Function
$616,897Matthew Charlton Good · University Of Pennsylvania · R56 · FY2025 · EB
Overcoming the immune-suppressive tumor microenvironment through in situ vaccination nanotechnology
$616,764Nicole Franziska Steinmetz · Case Western Reserve University · U01 · FY2017 · CA
Applying pathomics to establish a biosignature for aggressive skin melanoma
$616,736Yvonne Margaret Saenger · Albert Einstein College Of Medicine · R01 · FY2023 · CA
Exploiting the Mechanobiology of PD-1 for Cancer Immunotherapy
$616,381Cheng Zhu · Georgia Institute Of Technology · U01 · FY2023 · CA
Multimeric Ligands for Targeting Melanoma
$616,331Robert J Gillies · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2009 · CA
Validating and Characterizing a New Melanoma Therapeutic Target
$616,207Sara A Courtneidge · Oregon Health & Science University · R01 · FY2019 · CA
Network Lead Academic Participating Site Grant from the Roswell Cancer Inst.
$616,000Ellis G Levine · Roswell Park Cancer Institute Corp · U10 · FY2016 · CA
Network Lead Academic Participating Site Grant from the Roswell Cancer Inst.
$616,000Ellis G Levine · Roswell Park Cancer Institute Corp · U10 · FY2014 · CA
Impact of mutation burden on cancer growth and the immune landscape
$615,901Eileen White · Rutgers Biomedical And Health Sciences · R01 · FY2024 · CA
Immunogenetic Study of Infectious Diseases and Cancer
$615,901Francesco M Marincola · Clinical Center · Z01 · FY2007 · CL
IL-2 Family Cytokines and their Receptors--Biology of the IL-7/TSLP Systems
$615,820Warren J Leonard · National Heart, Lung, And Blood Institute · ZIA · FY2023 · HL
Development of Virtual Tumor
$615,609Massachusetts General Hospital · U56 · FY2005 · CA
Defining neoantigen immunodominance for antigen selection and biomarker discovery in human pancreatic cancer immunotherapy
$615,450Vinod P Balachandran · Sloan-Kettering Inst Can Research · U01 · FY2020 · CA